Protocol
12-076
Full Title
A Phase II Study of the HSP90 Inhibitor, AUY922, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET
Purpose
In essential thrombocythemia, the bone marrow makes too many platelets (blood-clotting cells). In polycythemia vera, the body makes too many red blood cells. Myelofibrosis is a disorder of the bone marrow in which the marrow is replaced by scar (fibrous) tissue. Myelofibrosis can develop after essential thrombocythemia or polycythemia vera, or on its own (“primary myelofibrosis”).
The purpose of this study is to assess the safety and effectiveness of an investigational drug called AUY922 in patients with primary myelofibrosis or myelofibrosis that has developed after thrombocythemia or polycythemia vera, and which is not responding to standard therapies. AUY922 works by inhibiting a protein called HSP90, which plays a central role in myelofibrosis. It is given intravenously (by vein).
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have primary myelofibrosis or myelofibrosis that has developed after thrombocythemia or polycythemia vera, and which is not responding to standard therapies
- At least 4 weeks must have passed since completion of prior systemic therapy (48 hours since hydroxyurea) and entry into the study.
- Patients must be able to be ambulatory for more than half of their normal waking hours.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Ellin Berman at 212-639-7762.
Disease(s)
Hematology: Hematologic Disorders
Hematology: Hematologic Malignancies
Leukemia: Myeloproliferative Neoplasm
Locations
ClinicalTrials.gov
Related Diseases
